Related Experiment Videos
ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.
Gianluca Severi1, Graham G Giles, Melissa C Southey
1Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
Journal of the National Cancer Institute
|June 5, 2003
Summary
This study found no evidence linking ELAC2 gene variations to prostate cancer risk or prostate-specific antigen (PSA) levels. Further research confirms these polymorphisms do not impact cancer development or detection markers.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- The ELAC2 gene, also known as HPC2, has been investigated for its potential role in prostate cancer susceptibility.
- Conflicting results exist regarding the association of ELAC2 polymorphisms (Ser217Leu and Ala541Thr) with prostate cancer risk.
- Previous studies often influenced subject selection by prostate-specific antigen (PSA) levels, necessitating further investigation.
Purpose of the Study:
- To investigate the association between ELAC2 gene polymorphisms and prostate cancer risk.
- To evaluate the influence of subject selection based on PSA levels on this association.
- To conduct a meta-analysis combining existing data with new findings.
Main Methods:
- A population-based study in Australia genotyped 825 cases and 732 controls for ELAC2 Ser217Leu and Ala541Thr polymorphisms.
- Odds ratios (ORs) for prostate cancer were calculated using logistic and polytomous regression.
- A meta-analysis integrated data from seven published studies, and linear regression analyzed genotype association with PSA levels in controls.
Main Results:
- No significant association was found between ELAC2 polymorphisms and prostate cancer risk (ORs for Leu217 homozygotes: 0.74; Thr541 variants: 1.01).
- Excluding control subjects with elevated PSA levels did not alter the observed ORs.
- No statistically significant association was detected between genotype frequencies and PSA levels in control subjects (P>.4).
- Meta-analysis pooled OR estimates also showed no significant association for either polymorphism.
Conclusions:
- The study provides no evidence supporting an association between ELAC2 polymorphisms (Ser217Leu and Ala541Thr) and prostate cancer.
- ELAC2 gene variations do not appear to be linked to prostate-specific antigen (PSA) levels.
- The findings suggest ELAC2 is unlikely to be a significant susceptibility gene for prostate cancer.